Amgen/Takeda To Re-start Motesanib Lung Cancer Trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amgen and partner Takeda are getting set to re-start a Phase III trial of the vascular endothelial growth factor inhibitor motesanib in non-small cell lung cancer, after a conditional go-ahead from an independent data monitoring committee